Latest & greatest articles for dabigatran

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on dabigatran or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on dabigatran and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for dabigatran

41. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.

Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. BACKGROUND: Dabigatran, which is administered in a fixed dose and does not require laboratory monitoring, may be suitable for extended treatment of venous thromboembolism. METHODS: In two double-blind, randomized trials, we compared dabigatran at a dose of 150 mg twice daily with warfarin (active-control study) or with placebo (placebo-control study) in patients with venous thromboembolism who had completed at least 3 (...) initial months of therapy. RESULTS: In the active-control study, recurrent venous thromboembolism occurred in 26 of 1430 patients in the dabigatran group (1.8%) and 18 of 1426 patients in the warfarin group (1.3%) (hazard ratio with dabigatran, 1.44; 95% confidence interval [CI], 0.78 to 2.64; P=0.01 for noninferiority). Major bleeding occurred in 13 patients in the dabigatran group (0.9%) and 25 patients in the warfarin group (1.8%) (hazard ratio, 0.52; 95% CI, 0.27 to 1.02). Major or clinically

NEJM2013

42. New oral anticoagulants apixaban (Eliquis?), dabigatran (Pradaxa) and rivaroxaban (Xarelto?)

New oral anticoagulants apixaban (Eliquis?), dabigatran (Pradaxa) and rivaroxaban (Xarelto?) New oral anticoagulants apixaban (Eliquis▼), dabigatran (Pradaxa) and rivaroxaban (Xarelto▼) Drug Safety Update - GOV.UK GOV.UK uses cookies to make the site simpler. Search New oral anticoagulants apixaban (Eliquis▼), dabigatran (Pradaxa) and rivaroxaban (Xarelto▼) From: Therapeutic area: Risk of serious haemorrhage—clarified contraindications apply to all 3 medicines. Article update September 2016 (...) : In November 2015, idarucizumab (Praxbind▼) was granted a European licence as a specific reversal agent for dabigatran. Idarucizumab is indicated for adults treated with dabigatran when rapid reversal of its anticoagulant effects is required for emergency surgery/urgent procedures, or in life-threatening or uncontrolled bleeding. Further information about this medicine is available on the website of the Article date: October 2013 Dabigatran (Pradaxa) is a potent, orally active, direct inhibitor of free

MHRA Drug Safety Update2013

43. Dabigatran (Pradaxa): contraindicated in patients with prosthetic heart valve(s) requiring anti-coagulant treatment

Dabigatran (Pradaxa): contraindicated in patients with prosthetic heart valve(s) requiring anti-coagulant treatment Dabigatran (Pradaxa): contraindicated in patients with prosthetic heart valve(s) requiring anti-coagulant treatment Drug Safety Update - GOV.UK GOV.UK uses cookies to make the site simpler. Search Dabigatran (Pradaxa): contraindicated in patients with prosthetic heart valve(s) requiring anti-coagulant treatment From: Published: 25 March 2013 Therapeutic area: and Risk (...) of thrombosis and haemorrhage in patients with prosthetic heart valve(s) requiring anti-coagulant treatment. Article date: March 2013 Dabigatran (Pradaxa) is a reversible inhibitor of free thrombin, fibrin-bound thrombin, and thrombin-induced platelet aggregation. It is licensed for primary prevention of venous thromboembolic events in adults who have had elective total hip or knee replacement surgery (at 220 mg/day), and for prevention of stroke and systemic embolism in adults with non-valvular

MHRA Drug Safety Update2013

45. Dabigatran associated with increased risk of acute coronary events

Dabigatran associated with increased risk of acute coronary events Dabigatran associated with increased risk of acute coronary events | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Dabigatran associated with increased risk of acute coronary events Article Text Electronic pages Dabigatran associated with increased risk of acute coronary events Payal Kohli 1 , Christopher Paul Cannon 2 Statistics from Altmetric.com No Altmetric data available for this article. Commentary on: Uchino K , Hernandez AV . Dabigatran association with higher risk of acute

Evidence-Based Medicine (Requires free registration)2013

46. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack

Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack Kamel H (...) , Johnston SC, Easton JD, Kim AS Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to assess the cost-effectiveness of dabigatran, compared with warfarin, in patients with atrial fibrillation and a history of stroke or

NHS Economic Evaluation Database.2013

47. The Effectiveness of Prothrombin Complex Concentrate in Reversing the Anticoagulant Activity of the Oral Director Thrombin Inhibitor Dabigatran (Pradaxa®): A Review of Human Studies

The Effectiveness of Prothrombin Complex Concentrate in Reversing the Anticoagulant Activity of the Oral Director Thrombin Inhibitor Dabigatran (Pradaxa®): A Review of Human Studies "The Effectiveness of Prothrombin Complex Concentrate in Reversing the " by Bridget Barron < > > > > > Title Author Date of Award 8-10-2013 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies First Advisor Annjanette Sommers Rights . Abstract Dabigatran is an oral direct (...) thrombin inhibitor approved by the US FDA for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. Dabigatran is rapidly replacing traditional anticoagulants, such as warfarin, despite the fact that clinicians have very little experience with dabigatran induced bleeding and no reliable therapeutic agent to reverse its effects. Prothrombin complex concentrate is effective at reversing traditional anticoagulants as it contains clotting factors, including

Pacific University EBM Capstone Project2013

48. Dabigatran Compared to Warfarin in the Reduction of Stroke Risk in Patients With Atrial Fibrillation

Dabigatran Compared to Warfarin in the Reduction of Stroke Risk in Patients With Atrial Fibrillation "Dabigatran Compared to Warfarin in the Reduction of Stroke Risk in Pat" by Thomas S. Haslam < > > > > > Title Author Date of Award Summer 8-10-2013 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies First Advisor James Ferguson, PA-C Second Advisor Annjanette Sommers, PA-C Rights . Abstract Background: Atrial fibrillation (AF) is the most common cardiac (...) available for over 60 years. Warfarin is effective, but dated compared to newer drugs of its class and associated with inherent difficulties in treatment. Dabigatran, a new anticoagulant that promises to be easier to administer, may reduce the risk of stroke even further than warfarin. Is dabigatran a better option than warfarin in reducing stroke in patients with AF? Method: Exhaustive search of available medical literature was done using CINAHL, Medline-OVID, and Academic Research Premiere using

Pacific University EBM Capstone Project2013

49. Pradaxa (dabigatran etexilate mesylate)

Pradaxa (dabigatran etexilate mesylate) Drug Approval Package: PRADAXA (dabigatran etexilate mesylate) NDA #022512 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - PRADAXA (dabigatran etexilate mesylate) Capsules Company: Boehringer Ingelheim Pharmaceuticals, Inc. Application No.: 022512 Approval Date: 10/19/2010 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF

FDA - Drug Approval Package2013

50. Dabigatran versus Warfarin in Patients with Mechanical Heart Valves.

Dabigatran versus Warfarin in Patients with Mechanical Heart Valves. 23991661 2013 09 26 2013 10 17 2015 11 19 1533-4406 369 13 2013 Sep 26 The New England journal of medicine N. Engl. J. Med. Dabigatran versus warfarin in patients with mechanical heart valves. 1206-14 10.1056/NEJMoa1300615 Dabigatran is an oral direct thrombin inhibitor that has been shown to be an effective alternative to warfarin in patients with atrial fibrillation. We evaluated the use of dabigatran in patients (...) with mechanical heart valves. In this phase 2 dose-validation study, we studied two populations of patients: those who had undergone aortic- or mitral-valve replacement within the past 7 days and those who had undergone such replacement at least 3 months earlier. Patients were randomly assigned in a 2:1 ratio to receive either dabigatran or warfarin. The selection of the initial dabigatran dose (150, 220, or 300 mg twice daily) was based on kidney function. Doses were adjusted to obtain a trough plasma level

NEJM2013

52. RE?LY: Dabigatran versus Warfarin in Patients with Atrial Fibrillation

RE?LY: Dabigatran versus Warfarin in Patients with Atrial Fibrillation

RxFiles2013

53. Dabigatran for stroke prevention in atrial fibrillation: a review of the evidence on safety

Dabigatran for stroke prevention in atrial fibrillation: a review of the evidence on safety Dabigatran for stroke prevention in atrial fibrillation: a review of the evidence on safety Dabigatran for stroke prevention in atrial fibrillation: a review of the evidence on safety CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH (...) . Dabigatran for stroke prevention in atrial fibrillation: a review of the evidence on safety. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2012 Authors' conclusions Bleeding is typically the main safety issue of concern with all anticoagulants, including dabigatran. In RE-LY, the major randomized controlled trial (RCT) comparing dabigatran with warfarin, the risk of severe bleeding was reduced with the lower 110-mg dose of dabigatran compared with adjusted-dose warfarin

Health Technology Assessment (HTA) Database.2012

54. Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons

Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic (...) ), dabigatran (220mg or 150mg) or apixaban (5mg) with enoxaparin in patients who underwent total hip or knee replacement were eligible for inclusion. Trials were required to assess an approved regimen for enoxaparin: 40mg once daily from 12 hours before surgery (Europe) or 30mg twice daily from 12 to 24 hours after surgery (North America). The primary outcome was symptomatic venous thromboembolism defined as deep vein thrombosis (DVT) or pulmonary embolism. Secondary outcomes were composites of total venous

DARE.2012

55. Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin: Results From the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial

Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin: Results From the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial 22700854 2012 07 17 2012 10 02 2015 11 19 1524-4539 126 3 2012 Jul 17 Circulation Circulation Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. 343-8 10.1161 (...) /CIRCULATIONAHA.111.090464 Dabigatran reduces ischemic stroke in comparison with warfarin; however, given the lack of antidote, there is concern that it might increase bleeding when surgery or invasive procedures are required. The current analysis was undertaken to compare the periprocedural bleeding risk of patients in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial treated with dabigatran and warfarin. Bleeding rates were evaluated from 7 days before until 30 days after invasive

EvidenceUpdates2012

56. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation

Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation Kansal AR, Sorensen SV, Gani R, Robinson P, Pan F, Plumb JM, Cowie MR Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study assessed the cost-effectiveness of dabigatran etexilate compared with warfarin, aspirin, or no therapy for the prevention of stroke and systemic embolism in patients with heart atrial fibrillation

NHS Economic Evaluation Database.2012

58. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective

Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective Sorensen SV, Kansal AR, Connolly S, Peng S, Linnehan J (...) , Bradley-Kennedy C, Plumb JM Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study investigated the cost-effectiveness of dabigatran etexilate versus warfarin (trial data) or usual care (warfarin, aspirin, or no treatment) for stroke

NHS Economic Evaluation Database.2012

59. Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses

Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses Pink J, Lane S, Pirmohamed M, Hughes DA Record (...) Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of dabigatran etexilate and warfarin in patients with non-valvular atrial fibrillation and a moderate-to-high risk of stroke. Dabigatran 110mg

NHS Economic Evaluation Database.2012

60. Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation (TA249)

Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation (TA249) Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation | Guidance and guidelines | NICE Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation Technology appraisal guidance [TA249] Published date: 15 March 2012 Share Guidance on dabigatran etexilate (Pradaxa) for preventing stroke and systemic embolism in adults

National Institute for Health and Clinical Excellence - Technology Appraisals2012